CONCLUSIONS: Findings from this study suggest that patients with large (> 2 cm) peripheral giant cell granuloma lesions are more likely to be women with lower oral hygiene scores and xerostomia.

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...

“The approval of ROMVIMZA provides a new, much-needed, well-tolerated, and effective treatment option for people suffering ... TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or ...

AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...

Peripheral T-cell lymphomas are a rare and heterogeneous type of lymphoma, with geographical and ethnic variations in histological subtypes that differ across the world.1 In The Lancet Haematology, ...

William Tap led the development of vimseltinib for tenosynovial giant cell tumor. The U.S. Food and Drug Administration ... “This approval is an exciting advance for patients with TGCT, who need ...

AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with ...

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) In the MOTION Phase 3 study, ROMVIMZA met primary ...

A plan to monitor, control the spread of and ultimately eradicate the invasive weed species, Giant Hogweed, in Perth County has been deferred for consideration in 2026 as Perth County staff make ...